|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TAB1 |
Gene summary for TAB1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TAB1 | Gene ID | 10454 |
| Gene name | TGF-beta activated kinase 1 (MAP3K7) binding protein 1 | |
| Gene Alias | 3'-Tab1 | |
| Cytomap | 22q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A8K6K3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10454 | TAB1 | LZE24T | Human | Esophagus | ESCC | 2.81e-14 | 2.02e-01 | 0.0596 |
| 10454 | TAB1 | P1T-E | Human | Esophagus | ESCC | 1.40e-06 | 2.42e-01 | 0.0875 |
| 10454 | TAB1 | P2T-E | Human | Esophagus | ESCC | 4.13e-14 | 2.02e-01 | 0.1177 |
| 10454 | TAB1 | P4T-E | Human | Esophagus | ESCC | 5.53e-03 | 1.19e-01 | 0.1323 |
| 10454 | TAB1 | P5T-E | Human | Esophagus | ESCC | 1.31e-04 | 9.64e-02 | 0.1327 |
| 10454 | TAB1 | P8T-E | Human | Esophagus | ESCC | 2.80e-10 | 1.14e-01 | 0.0889 |
| 10454 | TAB1 | P9T-E | Human | Esophagus | ESCC | 1.89e-06 | 1.45e-01 | 0.1131 |
| 10454 | TAB1 | P10T-E | Human | Esophagus | ESCC | 7.11e-06 | 1.44e-01 | 0.116 |
| 10454 | TAB1 | P11T-E | Human | Esophagus | ESCC | 3.63e-08 | 3.05e-01 | 0.1426 |
| 10454 | TAB1 | P12T-E | Human | Esophagus | ESCC | 1.74e-11 | 2.48e-01 | 0.1122 |
| 10454 | TAB1 | P15T-E | Human | Esophagus | ESCC | 1.18e-13 | 2.62e-01 | 0.1149 |
| 10454 | TAB1 | P16T-E | Human | Esophagus | ESCC | 7.06e-16 | 2.73e-01 | 0.1153 |
| 10454 | TAB1 | P17T-E | Human | Esophagus | ESCC | 2.39e-04 | 2.82e-01 | 0.1278 |
| 10454 | TAB1 | P19T-E | Human | Esophagus | ESCC | 6.98e-04 | 2.65e-01 | 0.1662 |
| 10454 | TAB1 | P20T-E | Human | Esophagus | ESCC | 2.38e-07 | 1.85e-01 | 0.1124 |
| 10454 | TAB1 | P21T-E | Human | Esophagus | ESCC | 7.83e-10 | 2.34e-01 | 0.1617 |
| 10454 | TAB1 | P22T-E | Human | Esophagus | ESCC | 4.47e-08 | 1.69e-01 | 0.1236 |
| 10454 | TAB1 | P23T-E | Human | Esophagus | ESCC | 1.86e-10 | 2.66e-01 | 0.108 |
| 10454 | TAB1 | P24T-E | Human | Esophagus | ESCC | 5.09e-08 | 1.65e-01 | 0.1287 |
| 10454 | TAB1 | P26T-E | Human | Esophagus | ESCC | 4.54e-16 | 2.83e-01 | 0.1276 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
| GO:007190016 | Esophagus | ESCC | regulation of protein serine/threonine kinase activity | 227/8552 | 359/18723 | 1.12e-11 | 4.10e-10 | 227 |
| GO:00715599 | Esophagus | ESCC | response to transforming growth factor beta | 157/8552 | 256/18723 | 2.95e-07 | 4.23e-06 | 157 |
| GO:00715609 | Esophagus | ESCC | cellular response to transforming growth factor beta stimulus | 151/8552 | 250/18723 | 1.78e-06 | 2.10e-05 | 151 |
| GO:00719029 | Esophagus | ESCC | positive regulation of protein serine/threonine kinase activity | 124/8552 | 200/18723 | 2.27e-06 | 2.61e-05 | 124 |
| GO:004586018 | Esophagus | ESCC | positive regulation of protein kinase activity | 219/8552 | 386/18723 | 6.91e-06 | 6.97e-05 | 219 |
| GO:003367420 | Esophagus | ESCC | positive regulation of kinase activity | 260/8552 | 467/18723 | 7.26e-06 | 7.22e-05 | 260 |
| GO:00303239 | Esophagus | ESCC | respiratory tube development | 112/8552 | 181/18723 | 7.82e-06 | 7.69e-05 | 112 |
| GO:00071799 | Esophagus | ESCC | transforming growth factor beta receptor signaling pathway | 121/8552 | 198/18723 | 8.26e-06 | 8.03e-05 | 121 |
| GO:00605417 | Esophagus | ESCC | respiratory system development | 123/8552 | 203/18723 | 1.26e-05 | 1.15e-04 | 123 |
| GO:00303249 | Esophagus | ESCC | lung development | 109/8552 | 177/18723 | 1.40e-05 | 1.27e-04 | 109 |
| GO:000717810 | Esophagus | ESCC | transmembrane receptor protein serine/threonine kinase signaling pathway | 195/8552 | 355/18723 | 2.58e-04 | 1.58e-03 | 195 |
| GO:00434055 | Esophagus | ESCC | regulation of MAP kinase activity | 102/8552 | 177/18723 | 8.89e-04 | 4.55e-03 | 102 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
| hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa05130211 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
| hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
| hsa05170210 | Esophagus | ESCC | Human immunodeficiency virus 1 infection | 147/4205 | 212/8465 | 3.37e-09 | 3.53e-08 | 1.81e-08 | 147 |
| hsa0513526 | Esophagus | ESCC | Yersinia infection | 100/4205 | 137/8465 | 1.80e-08 | 1.59e-07 | 8.12e-08 | 100 |
| hsa05417211 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
| hsa051619 | Esophagus | ESCC | Hepatitis B | 108/4205 | 162/8465 | 7.68e-06 | 4.15e-05 | 2.12e-05 | 108 |
| hsa0514525 | Esophagus | ESCC | Toxoplasmosis | 76/4205 | 112/8465 | 6.83e-05 | 2.90e-04 | 1.48e-04 | 76 |
| hsa0462122 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
| hsa040645 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
| hsa05132310 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa0516937 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
| hsa05131310 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa05130310 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
| hsa0466817 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
| hsa0517038 | Esophagus | ESCC | Human immunodeficiency virus 1 infection | 147/4205 | 212/8465 | 3.37e-09 | 3.53e-08 | 1.81e-08 | 147 |
| hsa05135111 | Esophagus | ESCC | Yersinia infection | 100/4205 | 137/8465 | 1.80e-08 | 1.59e-07 | 8.12e-08 | 100 |
| hsa05417310 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TAB1 | SNV | Missense_Mutation | rs146341900 | c.1006C>T | p.Arg336Cys | p.R336C | Q15750 | protein_coding | deleterious(0) | probably_damaging(0.943) | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
| TAB1 | deletion | Frame_Shift_Del | novel | c.1097delG | p.Gly366AlafsTer7 | p.G366Afs*7 | Q15750 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| TAB1 | SNV | Missense_Mutation | rs375269432 | c.1007N>A | p.Arg336His | p.R336H | Q15750 | protein_coding | deleterious(0) | possibly_damaging(0.715) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TAB1 | SNV | Missense_Mutation | rs748314614 | c.505N>A | p.Val169Ile | p.V169I | Q15750 | protein_coding | tolerated(0.55) | benign(0) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| TAB1 | SNV | Missense_Mutation | rs746857619 | c.730N>A | p.Gly244Arg | p.G244R | Q15750 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TAB1 | SNV | Missense_Mutation | c.493G>T | p.Gly165Trp | p.G165W | Q15750 | protein_coding | deleterious(0) | possibly_damaging(0.889) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TAB1 | SNV | Missense_Mutation | rs779843526 | c.310N>T | p.Arg104Cys | p.R104C | Q15750 | protein_coding | deleterious(0.01) | possibly_damaging(0.813) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TAB1 | deletion | Frame_Shift_Del | c.1296delC | p.Thr433ProfsTer9 | p.T433Pfs*9 | Q15750 | protein_coding | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |||
| TAB1 | deletion | Frame_Shift_Del | c.1292delN | p.Thr433ProfsTer9 | p.T433Pfs*9 | Q15750 | protein_coding | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |||
| TAB1 | SNV | Missense_Mutation | novel | c.607C>A | p.Leu203Met | p.L203M | Q15750 | protein_coding | deleterious(0.01) | possibly_damaging(0.794) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |